Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Pentagamavunon-1 (PGV-1) is an oral Curcumin analog that effectively induces apoptosis through multiple molecular mechanisms. It primarily targets and inhibits key angiogenic factors, including cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF), which play crucial roles in mediating cell proliferation and survival. Additionally, PGV-1 possesses the ability to inhibit the activation of NF-κB, further enhancing its apoptotic effects. [1]
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | 5 days | $ 38.00 | |
5 mg | 5 days | $ 59.00 | |
1 mL * 10 mM (in DMSO) | 5 days | $ 59.00 |
Description | Pentagamavunon-1 (PGV-1) is an oral Curcumin analog that effectively induces apoptosis through multiple molecular mechanisms. It primarily targets and inhibits key angiogenic factors, including cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF), which play crucial roles in mediating cell proliferation and survival. Additionally, PGV-1 possesses the ability to inhibit the activation of NF-κB, further enhancing its apoptotic effects. [1] |
In vitro | Pentagamavunon-1 (PGV-1) at concentrations ranging from 1 to 20 μM significantly enhances the cytotoxic effect of 5-fluorouracil (5-FU) on WiDr human colon carcinoma cells, as demonstrated through various incubation periods of 6, 12, 24, and 48 hours, thus suggesting a potentiated anti-cancer effect. Additionally, at lower concentrations (1, 2.5, 5, and 10 μM), PGV-1 distinctly influences cell cycle progression, leading to G2/M phase arrest after 24 hours of treatment. This indicates PGV-1’s dual mechanism of action: enhancing 5-FU cytotoxicity and altering cell cycle dynamics. |
In vivo | Pentagamavunon-1 (PGV-1, po, 20 mg/kg) demonstrated significant anti-tumor effects in a Patient-Derived Xenograft (PDX) model without apparent toxicity. This study involved administering PGV-1 orally at a dosage of 20 mg/kg every two days over a 20-day period to a human cancer cell xenograft mouse model. Results indicated a negligible impact on body weight, no reduction in white and red blood cell counts in the peripheral blood, and no adverse effects on behavior or macroscopic appearance. Therefore, PGV-1 effectively inhibited tumor growth in vivo without discernible negative effects on normal cell lineages. |
Molecular Weight | 348.43 |
Formula | C23H24O3 |
CAS No. | 27060-70-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Pentagamavunon-1 27060-70-4 inhibitor inhibit